Geoffrey L. Smith

University of Cambridge — United Kingdom

Immunology and Microbiology · Life Sciences

100h-index32.6kcitations504works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Poxvirus research and outbreaks(282), Herpesvirus Infections and Treatments(213), Virus-based gene therapy research(129), Plant Virus Research Studies(43), Bacteriophages and microbial interactions(43)

Publications501 total

Exit from naive pluripotency proceeds with variable latency but without asymmetric division to generate population heterogeneity
Stem Cell Reports·2026Open Access
Development of a replication-defective mpox virus platform for fundamental and therapeutic research
Nature Communications·2025Open Access
Modest Dose Escalation for Early-Stage Anal Cancer: Cancer Control and Toxicity Outcomes
International Journal of Radiation Oncology*Biology*Physics·2025
Development of a replication-defective MPXV platform for fundamental and therapeutic research
2025Open Access
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination
Nature Communications·2025· 6 citedOpen Access
Attenuation of the 2022 global outbreak monkeypox virus relative to its clade IIb ancestor
2025· 5 citedOpen Access
Recombinant Poxviruses
2024· 17 cited
The Design, Construction, and Use of Vaccinia Virus Recombinants
2024· 1 cited
The nuclear localization signal of monkeypox virus protein P2 orthologue is critical for inhibition of IRF3-mediated innate immunity
Emerging Microbes & Infections·2024· 9 citedOpen Access
Question prompt lists and caregiver question asking in pediatric specialty appointments: A randomized controlled trial
UNC Libraries·2024Open Access
HDAC5 enhances IRF3 activation and is targeted for degradation by protein C6 from orthopoxviruses including Monkeypox virus and Variola virus
Cell Reports·2024· 9 citedOpen Access
Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4
Journal of Virology·2024· 1 citedOpen Access
Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infection
Nature Communications·2023· 9 citedOpen Access
The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity
iScience·2023· 26 citedOpen Access
TRIM5α restricts poxviruses and is antagonized by CypA and the viral protein C6
Nature·2023· 31 citedOpen Access
ICTV Virus Taxonomy Profile: Poxviridae 2023
Journal of General Virology·2023· 73 citedOpen Access
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination
Cell Reports·2023· 7 citedOpen Access
Transcriptional reprogramming of natural killer cells by vaccinia virus shows both distinct and conserved features with mCMV
Frontiers in Immunology·2023· 4 citedOpen Access
Suppression of innate immunity by the vaccinia virus protein N1 promotes skin microbiota expansion and increased immune infiltration following vaccination
Journal of General Virology·2022· 1 citedOpen Access
Manipulation of innate immune signaling pathways by SARS-CoV-2 non-structural proteins
Frontiers in Microbiology·2022· 16 citedOpen Access
page 1 of 26Next →

Frequent Co-authors

Bernard Moss(11), Antonio Alcamı́(7), Julian Symons(5), Andrew Bowie(4), Andrew J. McMichael(4), M. Mackett(3), Tom Blanchard(3), Alain Vanderplasschen(3), Alain Townsend(3), Nathan W. Bartlett(3), Michael Hollinshead(3), Sarah C. Gilbert(2), Tomáš Hanke(2), Carolyn M. Hannan(2), Robert E. Sinden(2), Adrian V. S. Hill(2), Mansun Law(2), Jack R. Bennink(2), Luke O'neill(2), Tao Dong(2)